# Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension

> **NCT00263003** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 40 (—)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Irbesartan/hydrochlorothiazide
- **DRUG:** Irbesartan

## Key facts

- **NCT ID:** NCT00263003
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2007-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263003, "Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00263003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*